Stocksigma LogoStocksigma Logo

Ajanta Pharma Reports Robust Q2 FY27 With PAT Up 49% YoY

Ajanta Pharma reported strong Q2 FY27 consolidated revenue from operations of Rs. 1,794 cr., up 33% YoY. Adjusted EBITDA grew 47% YoY to Rs. 543 cr

Ajanta Pharma Reports Robust Q2 FY27 With PAT Up 49% YoY

Ajanta Pharma Ltd 路 Financial Result 路 30 Oct 2026, 6:29 pm

Ajanta Pharma Reports Robust Q2 FY27 With PAT Up 49% YoY Ajanta Pharma reported strong Q2 FY27 consolidated revenue from operations of Rs. 1,794 cr., up 33% YoY. Adjusted EBITDA grew 47% YoY to Rs. 543 cr. with margins at 30%, while net profit rose 49% YoY to Rs. 388 cr. (PAT margin at 22%). Branded generics revenue grew 23% YoY to Rs. 1,182 cr., supported by India (+16%), Asia (+18%), and Africa (+41%). US Generics posted 41% YoY growth to Rs. 484 cr. For H1 FY27, revenue reached Rs. 3,420 cr. (+29% YoY) with PAT of Rs. 722 cr. (+40% YoY).

Original exchange filing (PDF)

More announcements from Ajanta Pharma Ltd

All Ajanta Pharma Ltd announcements